NEW ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE AND PHOSPHODIESTERASE INHIBITORS WITH DUAL ACTION MECHANISM AND THEIR APPLICATION Russian patent published in 2021 - IPC C07D487/04 A61K31/519 A61P3/10 A61P15/10 A61P25/00 

FIELD: chemistry; pharmaceutics.

SUBSTANCE: present group of inventions relates to the field of chemistry and pharmaceutics, namely to a compound of the formula I or its pharmaceutically acceptable salt, where at least one of R₂, R₄ or R₅, each independently, includes at least one fragment of ONO₂ or ONO; R₁ is C₁-C₃-alkyl, optionally substituted with F; R₂ is H, C₁-C₃-alkyl, optionally substituted with OH, ONO, ONO₂; C(O)OH, C(O)OC₁-C₃-alkyl, CHO, CN, C(O)N(R₆)OR₇, CR₈=N-OR₉, CR₈=NR₁₂, CR₈=N-ONO₂, C₁-C₃-alkoxy; C₁-C₃-alkylene-Y, wherein Y is ONO, ONO₂, C(O)OH, C(O)OC₁-C₃-alkyl, CHO, CN, OH, OC(O)H, OC(O)-C₁-C₃-alkyl, C(O)N(R₆)OR₇, OC₁-C₃-alkylene-C(O)OH, OC₁-C₃-alkylene-C(O)OC₁-C₃-alkyl, OC₁-C₃-alkylene-C(O)N(R₆)OR₇, S(O_0-2)C₁-C₃-alkyl, CR₈=N-OR₉, CR₈=NR₁₂ or CR₈=N-ONO₂; R₃ is C₁-C₄-alkyl, optionally substituted with F, C₁-C₃-alkoxy, C₃-cycloalkyl; R₄ is C₁-C₆-alkyl, optionally substituted with C₃-C₆-cycloalkyl, C₁-C₆-alkoxy, F, ONO, ONO₂; R₅ is SO₂NR₁₃R₁₄; R₆ is H or C₁-C₃-alkyl; R₇ is H, C₁-C₃-alkyl, C₁-C₃-alkoxy; R₈ is H, CH₃ or C₂H₅; R₉ is H, C₁-C₃-alkyl, optionally substituted with OH, ONO, ONO₂, CN, COOH, COOC₁-C₃-alkyl, C₁-C₃-alkoxy, OC(O)H, OC(O)-C₁-C₃-alkyl, C(O)N(R₆)OR₇, OC₁-C₃-alkylene-C(O)OH; R₁₂ is C₁-C₃-alkyl, optionally substituted with OH, ONO, ONO₂, CN, COOH, COOC₁-C₃-alkyl, C₁-C₃-alkoxy, OC(O)H, OC(O)-C₁-C₃-alkyl, C(O)N(R₆)OR₇, OC₁-C₃-alkylene-C(O)OH; R₁₃ and R₁₄ together with a nitrogen atom, to which they are attached, form heterocyclic ring, wherein the specified heterocyclic ring is selected from piperidine and piperazine, wherein the specified heterocyclic ring is optionally substituted with R₁₅; R₁₅ is C₁-C₆-alkyl, optionally substituted with halogen, OH, ONO, ONO₂, C₁-C₃-alkoxy, C₁-C₃-halogenalkoxy, COOR₁₆, NR₁₇R₁₈, C=NR₁₉; R₁₆ is H or C₁-C₄-alkyl, optionally substituted with F, OH, ONO, ONO₂, NR₁₇R₁₈; R₁₇ and R₁₈, each independently, are H or C₁-C₄-alkyl, optionally substituted with ONO, ONO₂; R₁₉ is C₁-C₄-alkyl, optionally substituted with F, ONO, ONO₂; C₃-C₆-cycloalkyl, in addition, a pharmaceutical composition for inhibiting PDE5 based on the specified compounds is described.

EFFECT: new compounds are obtained and described that can be used to prevent a disease facilitated by PDE5 inhibition.

15 cl, 3 dwg, 2 tbl, 112 ex